Foix-Chavany-Marie Opercular Syndrome

Abstract

Foix-Chavany-Marie opercular syndrome is a severe form of pseudobulbar palsy caused by bilateral anterior opercular lesions (1,2). It is characterized by a loss of voluntary control of facial, lingual, pharyngeal and masticatory muscles in the presence of preserved reflexive and automatic functions of the same muscles (3,4). A 35-year-old male with diabetes had history of right leg deep vein thrombosis (DVT), which was treated since the age of 2 years. His sisters also had a history of DVT, and one of his sisters had had two abortions. The condition started one month ago as an inability to swallow, along with drooling of the saliva, which started suddenly when the patient developed the inability to speak with right side heaviness, mainly in the upper limb. An improvement in the weakness occurred five days later but he still could not speak; the patient then suddenly developed drooling and even an inability to open his mouth and move his tongue. The patient denied having history of hypertension. An examination of the central nervous system revealed a conscious patient with bilateral facial palsy, bulbar palsy, and normal power.

Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients – identification of novel single nucleotide polymorphism: Cross-sectional study

“…MTX is an intriguing subject for pharmacogenomics research. [43][44][45][46][47][48][49][50] Pharmacogenomics studies concerning RA have emphasized the identification of genetic markers that may predict a patient's clinical response or the development of side effects for a given therapy, as well as assessing potential interactions between a patient's genetic profile and environmental factors. [51][52][53] This field holds promise for advancing personalized medicine and enhancing RA treatment approaches; this is the first research in the current literature that examined the association between several TYMS genes (657334C > A, rs2853741T > C, rs2606241A > C, and rs2853742T > C SNPs) with MTX treatment response.…”

“…MTX is an intriguing subject for pharmacogenomics research. [43–50] Pharmacogenomics studies concerning RA have emphasized the identification of genetic markers that may predict a patient’s clinical response or the development of side effects for a given therapy, as well as assessing potential interactions between a patient’s genetic profile and environmental factors. [51–53]…”